Clinical cancer research
Recent successes:
-
Axillary node staging by ultrasonography and fine-needle aspiration cytology in patients with breast cancer.
Baruah BP, Goyal A, Young P, Douglas-Jones AG, Mansel RE, Br J Surg , Volume 97 , 5 (May 2010) pp.680-683
-
European
development of clofarabine as treatment for older patients with acute
myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK, J Clin Oncol , Volume 28 , 14 (May 2010) pp.2389-2395
-
Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12.
Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, de Graaf SS, van den Berg E, Burnett AK, Gibson BE, J Clin Oncol (May 2010)
Our objectives in this area are:
- Train clinicians and disseminate the results of ground breaking ALMANAC study in breast cancer which established the key role of sentinel node biopsy in the treatment of breast cancer.
Prof Robert Mansel,
- Continue to develop and run a world class clinical trials unit to support clinicians and investigators from any cancer area in the UK organising clinical trials, from the basic idea, to producing reliable evidence to chance practice.
Mr Gareth Griffiths and Wales Cancer Trials Unit
- Investigate the management of venous thromboembolism in advanced cancer and the anticancer effects of heparins.
Dr Simon Noble, Department of Pharmacology
- For breast cancer, to refine sentinel node analysis, to develop more powerful molecular markers of prognosis based on expression profiling, and to take out anti-HGF and anti-angiogenesis agents into early-phase clinical trials.
Prof Wen Jiang and Mr Amit Goyal,
- Conduct biomarker analysis in breast and colorectal cancer.
Prof Bharat Jasani, Prof Jeremy Cheadle and Prof Tim Maughan
- Investigate the responsiveness and resistance to Epidermal Growth Factor Receptor blockade in colorectal cancer.
Dr Richard Adams, Department of Pharmacology
- Investigate the prevalence HPV infection in screening population South Wales and the epidemology of HPV in cervical cancer.
Prof Alison Fiander, HPV Research Group
- Build on our strengths in phase 3 trials for solid tumours and the success of the Wales Cancer Trials Network to lead more national/international trials from Cardiff.
Wales Cancer Trials Network
Publications
- Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C, Oscier DG, Stankovic T, Pepper C, Baird DM, Leukemia, Volume 26, 4 (April 2012) pp.826-830 - Expression of CD200 on AML blasts directly suppresses memory T-cell function.
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, Tonks A, Leukemia (March 2012) - Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3(+) regulatory T cells.
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, Tonks A, Leukemia (March 2012) - Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.
Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C, Clin Cancer Res, Volume 18, 3 (February 2012) pp.678-687 - Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study.
Sharma A, Gentry-Maharaj A, Burnell M, Fourkala EO, Campbell S, Amso N, Seif MW, Ryan A, Parmar M, Jacobs I, Menon U, UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) None, Bjog, Volume 119, 2 (January 2012) pp.207-219